Bristol-Myers Squibb and Pfizer Announce FDA Approval of Eliquis for DVT

Bristol-Myers Squibb (NYSE: BMY  ) and Pfizer (NYSE: PFE  ) are ending their work week on a high note. The latter announced that a Supplemental New Drug application for the medication they developed together, Eliquis, has been conditionally approved by the Food and Drug Administration. The regulator gave the nod to the drug for the preventive treatment of deep vein thrombosis in patients who have undergone hip or knee replacement surgery.

Deep vein thrombosis is a condition in which a blood clot forms in a large vein. If the clot breaks and travels through the blood system, the condition could lead to a potentially fatal blockage of the main artery of the lung.

According to data cited by Pfizer, roughly 719,000 knee replacement surgeries and 332,000 hip replacement procedures are performed each year.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2876976, ~/Articles/ArticleHandler.aspx, 9/30/2014 10:22:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement